Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBT (2016 - 2025)

Veracyte's EBT history spans 14 years, with the latest figure at $40.6 million for Q4 2025.

  • For Q4 2025, EBT rose 1095.47% year-over-year to $40.6 million; the TTM value through Dec 2025 reached $68.2 million, up 165.37%, while the annual FY2025 figure was $68.2 million, 165.37% up from the prior year.
  • EBT for Q4 2025 was $40.6 million at Veracyte, up from $18.9 million in the prior quarter.
  • Across five years, EBT topped out at $40.6 million in Q4 2025 and bottomed at -$45.7 million in Q1 2021.
  • The 5-year median for EBT is -$8.2 million (2023), against an average of -$5.0 million.
  • The largest annual shift saw EBT crashed 785.56% in 2023 before it surged 1095.47% in 2025.
  • A 5-year view of EBT shows it stood at -$11.3 million in 2021, then soared by 69.46% to -$3.4 million in 2022, then plummeted by 785.56% to -$30.5 million in 2023, then skyrocketed by 111.15% to $3.4 million in 2024, then soared by 1095.47% to $40.6 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's EBT are $40.6 million (Q4 2025), $18.9 million (Q3 2025), and $1.2 million (Q2 2025).